nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP2D6—Hydroxyurea—psoriasis	0.07	0.102	CbGbCtD
Tolterodine—CYP2C19—Cholecalciferol—psoriasis	0.0558	0.0815	CbGbCtD
Tolterodine—CYP3A4—Calcitriol—psoriasis	0.0524	0.0765	CbGbCtD
Tolterodine—CYP2C9—Cholecalciferol—psoriasis	0.0464	0.0678	CbGbCtD
Tolterodine—CYP2D6—Cholecalciferol—psoriasis	0.0424	0.062	CbGbCtD
Tolterodine—CYP3A4—Methoxsalen—psoriasis	0.0407	0.0595	CbGbCtD
Tolterodine—CYP2C19—Prednisone—psoriasis	0.0387	0.0565	CbGbCtD
Tolterodine—CYP2C19—Cyclosporine—psoriasis	0.0367	0.0536	CbGbCtD
Tolterodine—CYP2C9—Cyclosporine—psoriasis	0.0305	0.0445	CbGbCtD
Tolterodine—CYP2D6—Cyclosporine—psoriasis	0.0279	0.0407	CbGbCtD
Tolterodine—CYP3A4—Cholecalciferol—psoriasis	0.027	0.0394	CbGbCtD
Tolterodine—CYP2C19—Dexamethasone—psoriasis	0.0242	0.0353	CbGbCtD
Tolterodine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0234	0.0342	CbGbCtD
Tolterodine—CYP3A4—Triamcinolone—psoriasis	0.0234	0.0342	CbGbCtD
Tolterodine—CYP2C9—Dexamethasone—psoriasis	0.0201	0.0293	CbGbCtD
Tolterodine—CYP3A4—Betamethasone—psoriasis	0.0201	0.0293	CbGbCtD
Tolterodine—CYP3A4—Prednisolone—psoriasis	0.0198	0.0289	CbGbCtD
Tolterodine—CYP3A4—Hydrocortisone—psoriasis	0.0188	0.0274	CbGbCtD
Tolterodine—CYP3A4—Prednisone—psoriasis	0.0187	0.0273	CbGbCtD
Tolterodine—CYP2D6—Dexamethasone—psoriasis	0.0184	0.0268	CbGbCtD
Tolterodine—CYP3A4—Cyclosporine—psoriasis	0.0177	0.0259	CbGbCtD
Tolterodine—CYP3A4—Dexamethasone—psoriasis	0.0117	0.0171	CbGbCtD
Tolterodine—Headache—Methoxsalen—psoriasis	0.000728	0.00244	CcSEcCtD
Tolterodine—Oedema—Hydroxyurea—psoriasis	0.000724	0.00243	CcSEcCtD
Tolterodine—Sinusitis—Cyclosporine—psoriasis	0.000721	0.00242	CcSEcCtD
Tolterodine—Infection—Hydroxyurea—psoriasis	0.000719	0.00241	CcSEcCtD
Tolterodine—Weight increased—Prednisolone—psoriasis	0.000714	0.00239	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Hydrocortisone—psoriasis	0.000712	0.00239	CcSEcCtD
Tolterodine—Diarrhoea—Calcitriol—psoriasis	0.000709	0.00238	CcSEcCtD
Tolterodine—Sinusitis—Mycophenolate mofetil—psoriasis	0.000704	0.00236	CcSEcCtD
Tolterodine—Weight increased—Hydrocortisone—psoriasis	0.000697	0.00234	CcSEcCtD
Tolterodine—Dry skin—Dexamethasone—psoriasis	0.000694	0.00233	CcSEcCtD
Tolterodine—Dry skin—Betamethasone—psoriasis	0.000694	0.00233	CcSEcCtD
Tolterodine—Bronchitis—Triamcinolone—psoriasis	0.000694	0.00233	CcSEcCtD
Tolterodine—Hypersensitivity—Acitretin—psoriasis	0.000679	0.00228	CcSEcCtD
Tolterodine—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.000677	0.00227	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Triamcinolone—psoriasis	0.000671	0.00225	CcSEcCtD
Tolterodine—Hallucination—Mycophenolate mofetil—psoriasis	0.00067	0.00225	CcSEcCtD
Tolterodine—Vertigo—Mycophenolic acid—psoriasis	0.000667	0.00224	CcSEcCtD
Tolterodine—Visual impairment—Cyclosporine—psoriasis	0.000665	0.00223	CcSEcCtD
Tolterodine—Oedema peripheral—Mycophenolate mofetil—psoriasis	0.000663	0.00222	CcSEcCtD
Tolterodine—Asthenia—Acitretin—psoriasis	0.000661	0.00222	CcSEcCtD
Tolterodine—Weight increased—Triamcinolone—psoriasis	0.000657	0.0022	CcSEcCtD
Tolterodine—Palpitations—Mycophenolic acid—psoriasis	0.000656	0.0022	CcSEcCtD
Tolterodine—Headache—Calcitriol—psoriasis	0.000649	0.00218	CcSEcCtD
Tolterodine—Visual impairment—Mycophenolate mofetil—psoriasis	0.000649	0.00217	CcSEcCtD
Tolterodine—Somnolence—Hydroxyurea—psoriasis	0.000643	0.00216	CcSEcCtD
Tolterodine—Flushing—Cyclosporine—psoriasis	0.000641	0.00215	CcSEcCtD
Tolterodine—Dyspepsia—Hydroxyurea—psoriasis	0.000637	0.00213	CcSEcCtD
Tolterodine—Arthralgia—Mycophenolic acid—psoriasis	0.000632	0.00212	CcSEcCtD
Tolterodine—Chest pain—Mycophenolic acid—psoriasis	0.000632	0.00212	CcSEcCtD
Tolterodine—Diarrhoea—Acitretin—psoriasis	0.000631	0.00211	CcSEcCtD
Tolterodine—Anxiety—Mycophenolic acid—psoriasis	0.00063	0.00211	CcSEcCtD
Tolterodine—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000629	0.00211	CcSEcCtD
Tolterodine—Fatigue—Hydroxyurea—psoriasis	0.000624	0.00209	CcSEcCtD
Tolterodine—Pain—Hydroxyurea—psoriasis	0.000619	0.00207	CcSEcCtD
Tolterodine—Constipation—Hydroxyurea—psoriasis	0.000619	0.00207	CcSEcCtD
Tolterodine—Dry mouth—Mycophenolic acid—psoriasis	0.000618	0.00207	CcSEcCtD
Tolterodine—Confusional state—Mycophenolic acid—psoriasis	0.000611	0.00205	CcSEcCtD
Tolterodine—Hallucination—Hydrocortisone—psoriasis	0.00061	0.00205	CcSEcCtD
Tolterodine—Dizziness—Acitretin—psoriasis	0.00061	0.00204	CcSEcCtD
Tolterodine—Dizziness—Fluocinolone Acetonide—psoriasis	0.000608	0.00204	CcSEcCtD
Tolterodine—Oedema—Mycophenolic acid—psoriasis	0.000606	0.00203	CcSEcCtD
Tolterodine—Visual impairment—Prednisolone—psoriasis	0.000605	0.00203	CcSEcCtD
Tolterodine—Dry skin—Prednisone—psoriasis	0.000605	0.00203	CcSEcCtD
Tolterodine—Infection—Mycophenolic acid—psoriasis	0.000602	0.00202	CcSEcCtD
Tolterodine—Feeling abnormal—Hydroxyurea—psoriasis	0.000596	0.002	CcSEcCtD
Tolterodine—Weight increased—Betamethasone—psoriasis	0.000596	0.002	CcSEcCtD
Tolterodine—Weight increased—Dexamethasone—psoriasis	0.000596	0.002	CcSEcCtD
Tolterodine—Flatulence—Cyclosporine—psoriasis	0.000592	0.00198	CcSEcCtD
Tolterodine—Tachycardia—Mycophenolic acid—psoriasis	0.000592	0.00198	CcSEcCtD
Tolterodine—Flatulence—Mycophenolate mofetil—psoriasis	0.000578	0.00194	CcSEcCtD
Tolterodine—Headache—Acitretin—psoriasis	0.000577	0.00194	CcSEcCtD
Tolterodine—Headache—Fluocinolone Acetonide—psoriasis	0.000576	0.00193	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Methotrexate—psoriasis	0.00057	0.00191	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000552	0.00185	CcSEcCtD
Tolterodine—Angioedema—Cyclosporine—psoriasis	0.000549	0.00184	CcSEcCtD
Tolterodine—Vertigo—Cyclosporine—psoriasis	0.00054	0.00181	CcSEcCtD
Tolterodine—Somnolence—Mycophenolic acid—psoriasis	0.000539	0.00181	CcSEcCtD
Tolterodine—Angioedema—Mycophenolate mofetil—psoriasis	0.000536	0.00179	CcSEcCtD
Tolterodine—Dyspepsia—Mycophenolic acid—psoriasis	0.000534	0.00179	CcSEcCtD
Tolterodine—Hypersensitivity—Hydroxyurea—psoriasis	0.000533	0.00179	CcSEcCtD
Tolterodine—Vertigo—Mycophenolate mofetil—psoriasis	0.000527	0.00176	CcSEcCtD
Tolterodine—Fatigue—Mycophenolic acid—psoriasis	0.000523	0.00175	CcSEcCtD
Tolterodine—Hallucination—Betamethasone—psoriasis	0.000521	0.00175	CcSEcCtD
Tolterodine—Hallucination—Dexamethasone—psoriasis	0.000521	0.00175	CcSEcCtD
Tolterodine—Asthenia—Hydroxyurea—psoriasis	0.000519	0.00174	CcSEcCtD
Tolterodine—Weight increased—Prednisone—psoriasis	0.000519	0.00174	CcSEcCtD
Tolterodine—Pain—Mycophenolic acid—psoriasis	0.000518	0.00174	CcSEcCtD
Tolterodine—Constipation—Mycophenolic acid—psoriasis	0.000518	0.00174	CcSEcCtD
Tolterodine—Palpitations—Mycophenolate mofetil—psoriasis	0.000518	0.00174	CcSEcCtD
Tolterodine—Arthralgia—Cyclosporine—psoriasis	0.000512	0.00171	CcSEcCtD
Tolterodine—Chest pain—Cyclosporine—psoriasis	0.000512	0.00171	CcSEcCtD
Tolterodine—Anxiety—Cyclosporine—psoriasis	0.00051	0.00171	CcSEcCtD
Tolterodine—Visual impairment—Betamethasone—psoriasis	0.000505	0.00169	CcSEcCtD
Tolterodine—Visual impairment—Dexamethasone—psoriasis	0.000505	0.00169	CcSEcCtD
Tolterodine—Dry mouth—Cyclosporine—psoriasis	0.0005	0.00168	CcSEcCtD
Tolterodine—Angioedema—Prednisolone—psoriasis	0.0005	0.00167	CcSEcCtD
Tolterodine—Feeling abnormal—Mycophenolic acid—psoriasis	0.000499	0.00167	CcSEcCtD
Tolterodine—Arthralgia—Mycophenolate mofetil—psoriasis	0.000499	0.00167	CcSEcCtD
Tolterodine—Chest pain—Mycophenolate mofetil—psoriasis	0.000499	0.00167	CcSEcCtD
Tolterodine—Anxiety—Mycophenolate mofetil—psoriasis	0.000497	0.00167	CcSEcCtD
Tolterodine—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000496	0.00166	CcSEcCtD
Tolterodine—Diarrhoea—Hydroxyurea—psoriasis	0.000495	0.00166	CcSEcCtD
Tolterodine—Confusional state—Cyclosporine—psoriasis	0.000494	0.00166	CcSEcCtD
Tolterodine—Vertigo—Prednisolone—psoriasis	0.000491	0.00165	CcSEcCtD
Tolterodine—Anaphylactic shock—Cyclosporine—psoriasis	0.00049	0.00164	CcSEcCtD
Tolterodine—Oedema—Cyclosporine—psoriasis	0.00049	0.00164	CcSEcCtD
Tolterodine—Dry mouth—Mycophenolate mofetil—psoriasis	0.000488	0.00164	CcSEcCtD
Tolterodine—Angioedema—Hydrocortisone—psoriasis	0.000488	0.00164	CcSEcCtD
Tolterodine—Infection—Cyclosporine—psoriasis	0.000487	0.00163	CcSEcCtD
Tolterodine—Confusional state—Mycophenolate mofetil—psoriasis	0.000482	0.00162	CcSEcCtD
Tolterodine—Vertigo—Hydrocortisone—psoriasis	0.00048	0.00161	CcSEcCtD
Tolterodine—Abdominal pain—Mycophenolic acid—psoriasis	0.000479	0.00161	CcSEcCtD
Tolterodine—Dizziness—Hydroxyurea—psoriasis	0.000479	0.0016	CcSEcCtD
Tolterodine—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000478	0.0016	CcSEcCtD
Tolterodine—Oedema—Mycophenolate mofetil—psoriasis	0.000478	0.0016	CcSEcCtD
Tolterodine—Infection—Mycophenolate mofetil—psoriasis	0.000475	0.00159	CcSEcCtD
Tolterodine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000467	0.00156	CcSEcCtD
Tolterodine—Angioedema—Triamcinolone—psoriasis	0.000459	0.00154	CcSEcCtD
Tolterodine—Hallucination—Prednisone—psoriasis	0.000454	0.00152	CcSEcCtD
Tolterodine—Headache—Hydroxyurea—psoriasis	0.000453	0.00152	CcSEcCtD
Tolterodine—Anxiety—Hydrocortisone—psoriasis	0.000453	0.00152	CcSEcCtD
Tolterodine—Vertigo—Triamcinolone—psoriasis	0.000452	0.00151	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000447	0.0015	CcSEcCtD
Tolterodine—Anaphylactic shock—Prednisolone—psoriasis	0.000446	0.0015	CcSEcCtD
Tolterodine—Oedema—Prednisolone—psoriasis	0.000446	0.0015	CcSEcCtD
Tolterodine—Dysuria—Methotrexate—psoriasis	0.000446	0.00149	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Methotrexate—psoriasis	0.000443	0.00148	CcSEcCtD
Tolterodine—Somnolence—Cyclosporine—psoriasis	0.000436	0.00146	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000436	0.00146	CcSEcCtD
Tolterodine—Anaphylactic shock—Hydrocortisone—psoriasis	0.000436	0.00146	CcSEcCtD
Tolterodine—Oedema—Hydrocortisone—psoriasis	0.000436	0.00146	CcSEcCtD
Tolterodine—Tachycardia—Prednisolone—psoriasis	0.000435	0.00146	CcSEcCtD
Tolterodine—Asthenia—Mycophenolic acid—psoriasis	0.000435	0.00146	CcSEcCtD
Tolterodine—Infection—Hydrocortisone—psoriasis	0.000433	0.00145	CcSEcCtD
Tolterodine—Dyspepsia—Cyclosporine—psoriasis	0.000432	0.00145	CcSEcCtD
Tolterodine—Tachycardia—Hydrocortisone—psoriasis	0.000425	0.00143	CcSEcCtD
Tolterodine—Somnolence—Mycophenolate mofetil—psoriasis	0.000425	0.00143	CcSEcCtD
Tolterodine—Flushing—Prednisone—psoriasis	0.000424	0.00142	CcSEcCtD
Tolterodine—Fatigue—Cyclosporine—psoriasis	0.000423	0.00142	CcSEcCtD
Tolterodine—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000421	0.00141	CcSEcCtD
Tolterodine—Pain—Cyclosporine—psoriasis	0.000419	0.00141	CcSEcCtD
Tolterodine—Constipation—Cyclosporine—psoriasis	0.000419	0.00141	CcSEcCtD
Tolterodine—Dry mouth—Triamcinolone—psoriasis	0.000419	0.0014	CcSEcCtD
Tolterodine—Angioedema—Dexamethasone—psoriasis	0.000417	0.0014	CcSEcCtD
Tolterodine—Angioedema—Betamethasone—psoriasis	0.000417	0.0014	CcSEcCtD
Tolterodine—Diarrhoea—Mycophenolic acid—psoriasis	0.000415	0.00139	CcSEcCtD
Tolterodine—Anaphylactic shock—Triamcinolone—psoriasis	0.00041	0.00138	CcSEcCtD
Tolterodine—Oedema—Triamcinolone—psoriasis	0.00041	0.00138	CcSEcCtD
Tolterodine—Vertigo—Dexamethasone—psoriasis	0.00041	0.00137	CcSEcCtD
Tolterodine—Vertigo—Betamethasone—psoriasis	0.00041	0.00137	CcSEcCtD
Tolterodine—Pain—Mycophenolate mofetil—psoriasis	0.000409	0.00137	CcSEcCtD
Tolterodine—Constipation—Mycophenolate mofetil—psoriasis	0.000409	0.00137	CcSEcCtD
Tolterodine—Infection—Triamcinolone—psoriasis	0.000408	0.00137	CcSEcCtD
Tolterodine—Feeling abnormal—Cyclosporine—psoriasis	0.000404	0.00135	CcSEcCtD
Tolterodine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000401	0.00134	CcSEcCtD
Tolterodine—Dizziness—Mycophenolic acid—psoriasis	0.000401	0.00134	CcSEcCtD
Tolterodine—Tachycardia—Triamcinolone—psoriasis	0.0004	0.00134	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000397	0.00133	CcSEcCtD
Tolterodine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000394	0.00132	CcSEcCtD
Tolterodine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000391	0.00131	CcSEcCtD
Tolterodine—Abdominal pain—Cyclosporine—psoriasis	0.000388	0.0013	CcSEcCtD
Tolterodine—Anxiety—Dexamethasone—psoriasis	0.000387	0.0013	CcSEcCtD
Tolterodine—Anxiety—Betamethasone—psoriasis	0.000387	0.0013	CcSEcCtD
Tolterodine—Dyspepsia—Hydrocortisone—psoriasis	0.000384	0.00129	CcSEcCtD
Tolterodine—Pain—Prednisolone—psoriasis	0.000382	0.00128	CcSEcCtD
Tolterodine—Headache—Mycophenolic acid—psoriasis	0.00038	0.00127	CcSEcCtD
Tolterodine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000378	0.00127	CcSEcCtD
Tolterodine—Fatigue—Hydrocortisone—psoriasis	0.000376	0.00126	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000374	0.00125	CcSEcCtD
Tolterodine—Pain—Hydrocortisone—psoriasis	0.000373	0.00125	CcSEcCtD
Tolterodine—Anaphylactic shock—Dexamethasone—psoriasis	0.000372	0.00125	CcSEcCtD
Tolterodine—Anaphylactic shock—Betamethasone—psoriasis	0.000372	0.00125	CcSEcCtD
Tolterodine—Oedema—Dexamethasone—psoriasis	0.000372	0.00125	CcSEcCtD
Tolterodine—Oedema—Betamethasone—psoriasis	0.000372	0.00125	CcSEcCtD
Tolterodine—Infection—Dexamethasone—psoriasis	0.00037	0.00124	CcSEcCtD
Tolterodine—Infection—Betamethasone—psoriasis	0.00037	0.00124	CcSEcCtD
Tolterodine—Feeling abnormal—Prednisolone—psoriasis	0.000368	0.00123	CcSEcCtD
Tolterodine—Visual impairment—Methotrexate—psoriasis	0.000368	0.00123	CcSEcCtD
Tolterodine—Tachycardia—Dexamethasone—psoriasis	0.000363	0.00122	CcSEcCtD
Tolterodine—Tachycardia—Betamethasone—psoriasis	0.000363	0.00122	CcSEcCtD
Tolterodine—Angioedema—Prednisone—psoriasis	0.000363	0.00122	CcSEcCtD
Tolterodine—Hypersensitivity—Cyclosporine—psoriasis	0.000361	0.00121	CcSEcCtD
Tolterodine—Dyspepsia—Triamcinolone—psoriasis	0.000361	0.00121	CcSEcCtD
Tolterodine—Feeling abnormal—Hydrocortisone—psoriasis	0.000359	0.0012	CcSEcCtD
Tolterodine—Vertigo—Prednisone—psoriasis	0.000357	0.0012	CcSEcCtD
Tolterodine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000356	0.00119	CcSEcCtD
Tolterodine—Fatigue—Triamcinolone—psoriasis	0.000354	0.00119	CcSEcCtD
Tolterodine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000352	0.00118	CcSEcCtD
Tolterodine—Asthenia—Cyclosporine—psoriasis	0.000352	0.00118	CcSEcCtD
Tolterodine—Pain—Triamcinolone—psoriasis	0.000351	0.00118	CcSEcCtD
Tolterodine—Abdominal pain—Hydrocortisone—psoriasis	0.000345	0.00115	CcSEcCtD
Tolterodine—Asthenia—Mycophenolate mofetil—psoriasis	0.000343	0.00115	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000339	0.00114	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000339	0.00114	CcSEcCtD
Tolterodine—Arthralgia—Prednisone—psoriasis	0.000338	0.00113	CcSEcCtD
Tolterodine—Feeling abnormal—Triamcinolone—psoriasis	0.000338	0.00113	CcSEcCtD
Tolterodine—Anxiety—Prednisone—psoriasis	0.000337	0.00113	CcSEcCtD
Tolterodine—Diarrhoea—Cyclosporine—psoriasis	0.000336	0.00112	CcSEcCtD
Tolterodine—Hypersensitivity—Prednisolone—psoriasis	0.000329	0.0011	CcSEcCtD
Tolterodine—Dyspepsia—Betamethasone—psoriasis	0.000328	0.0011	CcSEcCtD
Tolterodine—Dyspepsia—Dexamethasone—psoriasis	0.000328	0.0011	CcSEcCtD
Tolterodine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000327	0.0011	CcSEcCtD
Tolterodine—Dizziness—Cyclosporine—psoriasis	0.000324	0.00109	CcSEcCtD
Tolterodine—Oedema—Prednisone—psoriasis	0.000324	0.00109	CcSEcCtD
Tolterodine—Anaphylactic shock—Prednisone—psoriasis	0.000324	0.00109	CcSEcCtD
Tolterodine—Infection—Prednisone—psoriasis	0.000322	0.00108	CcSEcCtD
Tolterodine—Hypersensitivity—Hydrocortisone—psoriasis	0.000321	0.00108	CcSEcCtD
Tolterodine—Fatigue—Betamethasone—psoriasis	0.000321	0.00108	CcSEcCtD
Tolterodine—Fatigue—Dexamethasone—psoriasis	0.000321	0.00108	CcSEcCtD
Tolterodine—Pain—Betamethasone—psoriasis	0.000318	0.00107	CcSEcCtD
Tolterodine—Pain—Dexamethasone—psoriasis	0.000318	0.00107	CcSEcCtD
Tolterodine—Tachycardia—Prednisone—psoriasis	0.000316	0.00106	CcSEcCtD
Tolterodine—Dizziness—Mycophenolate mofetil—psoriasis	0.000316	0.00106	CcSEcCtD
Tolterodine—Asthenia—Hydrocortisone—psoriasis	0.000313	0.00105	CcSEcCtD
Tolterodine—Headache—Cyclosporine—psoriasis	0.000307	0.00103	CcSEcCtD
Tolterodine—Feeling abnormal—Betamethasone—psoriasis	0.000307	0.00103	CcSEcCtD
Tolterodine—Feeling abnormal—Dexamethasone—psoriasis	0.000307	0.00103	CcSEcCtD
Tolterodine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000304	0.00102	CcSEcCtD
Tolterodine—Gastrointestinal pain—Betamethasone—psoriasis	0.000304	0.00102	CcSEcCtD
Tolterodine—Hypersensitivity—Triamcinolone—psoriasis	0.000302	0.00101	CcSEcCtD
Tolterodine—Headache—Mycophenolate mofetil—psoriasis	0.0003	0.001	CcSEcCtD
Tolterodine—Vertigo—Methotrexate—psoriasis	0.000298	0.001	CcSEcCtD
Tolterodine—Diarrhoea—Hydrocortisone—psoriasis	0.000298	0.000999	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Prednisone—psoriasis	0.000295	0.00099	CcSEcCtD
Tolterodine—Dizziness—Prednisolone—psoriasis	0.000295	0.000989	CcSEcCtD
Tolterodine—Asthenia—Triamcinolone—psoriasis	0.000294	0.000987	CcSEcCtD
Tolterodine—Abdominal pain—Betamethasone—psoriasis	0.000294	0.000986	CcSEcCtD
Tolterodine—Abdominal pain—Dexamethasone—psoriasis	0.000294	0.000986	CcSEcCtD
Tolterodine—Dizziness—Hydrocortisone—psoriasis	0.000288	0.000966	CcSEcCtD
Tolterodine—Dyspepsia—Prednisone—psoriasis	0.000285	0.000957	CcSEcCtD
Tolterodine—Arthralgia—Methotrexate—psoriasis	0.000283	0.000947	CcSEcCtD
Tolterodine—Chest pain—Methotrexate—psoriasis	0.000283	0.000947	CcSEcCtD
Tolterodine—Fatigue—Prednisone—psoriasis	0.00028	0.000937	CcSEcCtD
Tolterodine—Headache—Prednisolone—psoriasis	0.00028	0.000937	CcSEcCtD
Tolterodine—Constipation—Prednisone—psoriasis	0.000277	0.000929	CcSEcCtD
Tolterodine—Confusional state—Methotrexate—psoriasis	0.000273	0.000916	CcSEcCtD
Tolterodine—Headache—Hydrocortisone—psoriasis	0.000273	0.000915	CcSEcCtD
Tolterodine—Dizziness—Triamcinolone—psoriasis	0.000271	0.000909	CcSEcCtD
Tolterodine—Anaphylactic shock—Methotrexate—psoriasis	0.000271	0.000908	CcSEcCtD
Tolterodine—Infection—Methotrexate—psoriasis	0.000269	0.000902	CcSEcCtD
Tolterodine—Feeling abnormal—Prednisone—psoriasis	0.000267	0.000895	CcSEcCtD
Tolterodine—Asthenia—Betamethasone—psoriasis	0.000267	0.000895	CcSEcCtD
Tolterodine—Asthenia—Dexamethasone—psoriasis	0.000267	0.000895	CcSEcCtD
Tolterodine—Gastrointestinal pain—Prednisone—psoriasis	0.000265	0.000889	CcSEcCtD
Tolterodine—Headache—Triamcinolone—psoriasis	0.000257	0.000861	CcSEcCtD
Tolterodine—Abdominal pain—Prednisone—psoriasis	0.000256	0.000859	CcSEcCtD
Tolterodine—Diarrhoea—Betamethasone—psoriasis	0.000255	0.000854	CcSEcCtD
Tolterodine—Diarrhoea—Dexamethasone—psoriasis	0.000255	0.000854	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000247	0.000827	CcSEcCtD
Tolterodine—Dizziness—Dexamethasone—psoriasis	0.000246	0.000825	CcSEcCtD
Tolterodine—Dizziness—Betamethasone—psoriasis	0.000246	0.000825	CcSEcCtD
Tolterodine—Somnolence—Methotrexate—psoriasis	0.000241	0.000807	CcSEcCtD
Tolterodine—Hypersensitivity—Prednisone—psoriasis	0.000239	0.000801	CcSEcCtD
Tolterodine—Dyspepsia—Methotrexate—psoriasis	0.000239	0.000799	CcSEcCtD
Tolterodine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000236	0.014	CbGpPWpGaD
Tolterodine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000234	0.0138	CbGpPWpGaD
Tolterodine—Fatigue—Methotrexate—psoriasis	0.000234	0.000783	CcSEcCtD
Tolterodine—Headache—Dexamethasone—psoriasis	0.000233	0.000782	CcSEcCtD
Tolterodine—Headache—Betamethasone—psoriasis	0.000233	0.000782	CcSEcCtD
Tolterodine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000233	0.0138	CbGpPWpGaD
Tolterodine—Asthenia—Prednisone—psoriasis	0.000233	0.00078	CcSEcCtD
Tolterodine—Pain—Methotrexate—psoriasis	0.000232	0.000777	CcSEcCtD
Tolterodine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000231	0.0137	CbGpPWpGaD
Tolterodine—CHRM5—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000228	0.0135	CbGpPWpGaD
Tolterodine—Feeling abnormal—Methotrexate—psoriasis	0.000223	0.000748	CcSEcCtD
Tolterodine—Diarrhoea—Prednisone—psoriasis	0.000222	0.000743	CcSEcCtD
Tolterodine—Gastrointestinal pain—Methotrexate—psoriasis	0.000222	0.000743	CcSEcCtD
Tolterodine—CHRM4—G alpha (i) signalling events—HCAR2—psoriasis	0.000218	0.0129	CbGpPWpGaD
Tolterodine—Dizziness—Prednisone—psoriasis	0.000214	0.000719	CcSEcCtD
Tolterodine—Abdominal pain—Methotrexate—psoriasis	0.000214	0.000718	CcSEcCtD
Tolterodine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000208	0.0123	CbGpPWpGaD
Tolterodine—Headache—Prednisone—psoriasis	0.000203	0.000681	CcSEcCtD
Tolterodine—Hypersensitivity—Methotrexate—psoriasis	0.0002	0.000669	CcSEcCtD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000196	0.0116	CbGpPWpGaD
Tolterodine—Asthenia—Methotrexate—psoriasis	0.000194	0.000652	CcSEcCtD
Tolterodine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000191	0.0113	CbGpPWpGaD
Tolterodine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00019	0.0112	CbGpPWpGaD
Tolterodine—Diarrhoea—Methotrexate—psoriasis	0.000185	0.000621	CcSEcCtD
Tolterodine—Dizziness—Methotrexate—psoriasis	0.000179	0.000601	CcSEcCtD
Tolterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000173	0.0102	CbGpPWpGaD
Tolterodine—Headache—Methotrexate—psoriasis	0.00017	0.000569	CcSEcCtD
Tolterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000166	0.00981	CbGpPWpGaD
Tolterodine—CHRM1—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.00016	0.00948	CbGpPWpGaD
Tolterodine—CHRM3—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.00016	0.00945	CbGpPWpGaD
Tolterodine—CHRM2—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000158	0.00936	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—IL13—psoriasis	0.000155	0.00918	CbGpPWpGaD
Tolterodine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000154	0.00913	CbGpPWpGaD
Tolterodine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000152	0.00901	CbGpPWpGaD
Tolterodine—CHRM2—G alpha (i) signalling events—HCAR2—psoriasis	0.000145	0.00858	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—HCAR2—psoriasis	0.000132	0.0078	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—HCAR2—psoriasis	0.000126	0.00747	CbGpPWpGaD
Tolterodine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000125	0.0074	CbGpPWpGaD
Tolterodine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000123	0.0073	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000117	0.00691	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000116	0.00689	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000115	0.00682	CbGpPWpGaD
Tolterodine—CHRM4—G alpha (i) signalling events—CCL20—psoriasis	0.000113	0.00669	CbGpPWpGaD
Tolterodine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000111	0.00654	CbGpPWpGaD
Tolterodine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000109	0.00645	CbGpPWpGaD
Tolterodine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000107	0.00636	CbGpPWpGaD
Tolterodine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000107	0.00634	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000105	0.00618	CbGpPWpGaD
Tolterodine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000102	0.00601	CbGpPWpGaD
Tolterodine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000101	0.00596	CbGpPWpGaD
Tolterodine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.0001	0.00593	CbGpPWpGaD
Tolterodine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	9.94e-05	0.00588	CbGpPWpGaD
Tolterodine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	9.86e-05	0.00583	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—IL10—psoriasis	9.7e-05	0.00574	CbGpPWpGaD
Tolterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	9e-05	0.00532	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—HCAR2—psoriasis	8.9e-05	0.00526	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—HCAR2—psoriasis	8.87e-05	0.00524	CbGpPWpGaD
Tolterodine—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—psoriasis	8.85e-05	0.00524	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—HCAR2—psoriasis	8.78e-05	0.00519	CbGpPWpGaD
Tolterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	8.62e-05	0.0051	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—IL13—psoriasis	8.25e-05	0.00488	CbGpPWpGaD
Tolterodine—CHRM2—G alpha (i) signalling events—CCL20—psoriasis	7.53e-05	0.00446	CbGpPWpGaD
Tolterodine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.49e-05	0.00443	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—HCAR2—psoriasis	7.46e-05	0.00441	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—HCAR2—psoriasis	7.14e-05	0.00422	CbGpPWpGaD
Tolterodine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.09e-05	0.00419	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—CCL20—psoriasis	6.85e-05	0.00405	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—HCAR2—psoriasis	6.77e-05	0.004	CbGpPWpGaD
Tolterodine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.65e-05	0.00393	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—CCL20—psoriasis	6.56e-05	0.00388	CbGpPWpGaD
Tolterodine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.55e-05	0.00388	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—HCAR2—psoriasis	6.48e-05	0.00383	CbGpPWpGaD
Tolterodine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	6.37e-05	0.00377	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	6.07e-05	0.00359	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	6.05e-05	0.00358	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	5.99e-05	0.00354	CbGpPWpGaD
Tolterodine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	5.86e-05	0.00347	CbGpPWpGaD
Tolterodine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.73e-05	0.00339	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.31e-05	0.00314	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—IL10—psoriasis	5.16e-05	0.00305	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—HCAR2—psoriasis	5.03e-05	0.00297	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—HCAR2—psoriasis	5.01e-05	0.00296	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—HCAR2—psoriasis	4.96e-05	0.00294	CbGpPWpGaD
Tolterodine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.94e-05	0.00292	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—JUN—psoriasis	4.93e-05	0.00292	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.75e-05	0.00281	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CCL20—psoriasis	4.62e-05	0.00273	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—CCL20—psoriasis	4.61e-05	0.00272	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—HCAR2—psoriasis	4.57e-05	0.0027	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CCL20—psoriasis	4.56e-05	0.0027	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—HCAR2—psoriasis	4.55e-05	0.00269	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—HCAR2—psoriasis	4.51e-05	0.00267	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.31e-05	0.00255	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—HCAR2—psoriasis	4e-05	0.00237	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CCL20—psoriasis	3.87e-05	0.00229	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HCAR2—psoriasis	3.83e-05	0.00227	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CCL20—psoriasis	3.71e-05	0.00219	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—TNF—psoriasis	3.69e-05	0.00218	CbGpPWpGaD
Tolterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.61e-05	0.00213	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CCL20—psoriasis	3.52e-05	0.00208	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—LEP—psoriasis	3.51e-05	0.00208	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TAGAP—psoriasis	3.47e-05	0.00205	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—NDUFA5—psoriasis	3.42e-05	0.00202	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CCL20—psoriasis	3.37e-05	0.00199	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TAGAP—psoriasis	3.32e-05	0.00196	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—NOS2—psoriasis	3.27e-05	0.00194	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—PPARG—psoriasis	3.06e-05	0.00181	CbGpPWpGaD
Tolterodine—CHRM4—G alpha (i) signalling events—CXCL8—psoriasis	3.06e-05	0.00181	CbGpPWpGaD
Tolterodine—KCNH2—SIDS Susceptibility Pathways—IL6—psoriasis	2.98e-05	0.00176	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CYP2S1—psoriasis	2.91e-05	0.00172	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—CXCL8—psoriasis	2.82e-05	0.00167	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HCAR2—psoriasis	2.7e-05	0.0016	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HCAR2—psoriasis	2.69e-05	0.00159	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HCAR2—psoriasis	2.66e-05	0.00157	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—JUN—psoriasis	2.62e-05	0.00155	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CCL20—psoriasis	2.61e-05	0.00154	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CCL20—psoriasis	2.6e-05	0.00154	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CCL20—psoriasis	2.58e-05	0.00152	CbGpPWpGaD
Tolterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.54e-05	0.0015	CbGpPWpGaD
Tolterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.53e-05	0.0015	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—NFKB1—psoriasis	2.53e-05	0.00149	CbGpPWpGaD
Tolterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.43e-05	0.00144	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CCL20—psoriasis	2.37e-05	0.0014	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CCL20—psoriasis	2.36e-05	0.0014	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CCL20—psoriasis	2.34e-05	0.00138	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TAGAP—psoriasis	2.34e-05	0.00138	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TAGAP—psoriasis	2.33e-05	0.00138	CbGpPWpGaD
Tolterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.33e-05	0.00138	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TAGAP—psoriasis	2.31e-05	0.00137	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.29e-05	0.00136	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.22e-05	0.00131	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—JUN—psoriasis	2.17e-05	0.00128	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCL20—psoriasis	2.08e-05	0.00123	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.07e-05	0.00123	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.04e-05	0.00121	CbGpPWpGaD
Tolterodine—CHRM2—G alpha (i) signalling events—CXCL8—psoriasis	2.03e-05	0.0012	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.03e-05	0.0012	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCL20—psoriasis	1.99e-05	0.00118	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—TNF—psoriasis	1.97e-05	0.00116	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CYP2S1—psoriasis	1.89e-05	0.00112	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.89e-05	0.00112	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—CXCL8—psoriasis	1.85e-05	0.00109	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—CXCL8—psoriasis	1.77e-05	0.00105	CbGpPWpGaD
Tolterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.77e-05	0.00104	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.74e-05	0.00103	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP2S1—psoriasis	1.72e-05	0.00102	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.64e-05	0.000969	CbGpPWpGaD
Tolterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.63e-05	0.000966	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.62e-05	0.000957	CbGpPWpGaD
Tolterodine—CHRM2—SIDS Susceptibility Pathways—IL6—psoriasis	1.59e-05	0.000938	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—TP53—psoriasis	1.43e-05	0.000848	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CARM1—psoriasis	1.42e-05	0.00084	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCL20—psoriasis	1.4e-05	0.000828	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCL20—psoriasis	1.4e-05	0.000826	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCL20—psoriasis	1.38e-05	0.000818	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.34e-05	0.000791	CbGpPWpGaD
Tolterodine—CHRM1—Circadian rythm related genes—IL6—psoriasis	1.31e-05	0.000776	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CXCL8—psoriasis	1.25e-05	0.000738	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—CXCL8—psoriasis	1.24e-05	0.000736	CbGpPWpGaD
Tolterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.24e-05	0.000735	CbGpPWpGaD
Tolterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.24e-05	0.000733	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CXCL8—psoriasis	1.23e-05	0.000729	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SOCS1—psoriasis	1.14e-05	0.000677	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.14e-05	0.000672	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SOCS1—psoriasis	1.1e-05	0.000648	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—TYK2—psoriasis	1.09e-05	0.000645	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CXCL8—psoriasis	1.05e-05	0.000619	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—TYK2—psoriasis	1.04e-05	0.000618	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CXCL8—psoriasis	1e-05	0.000592	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.91e-06	0.000586	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CXCL8—psoriasis	9.5e-06	0.000562	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CARM1—psoriasis	9.23e-06	0.000546	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CXCL8—psoriasis	9.09e-06	0.000538	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.03e-06	0.000534	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CAT—psoriasis	8.73e-06	0.000517	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.63e-06	0.00051	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CARM1—psoriasis	8.49e-06	0.000502	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—LEP—psoriasis	8.44e-06	0.000499	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—APOE—psoriasis	8.44e-06	0.000499	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CARM1—psoriasis	8.42e-06	0.000498	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—APOE—psoriasis	8.08e-06	0.000478	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—LEP—psoriasis	8.08e-06	0.000478	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.87e-06	0.000465	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NFKBIA—psoriasis	7.87e-06	0.000465	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SOCS1—psoriasis	7.71e-06	0.000456	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SOCS1—psoriasis	7.69e-06	0.000455	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SOCS1—psoriasis	7.61e-06	0.00045	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NFKBIA—psoriasis	7.53e-06	0.000446	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—TYK2—psoriasis	7.35e-06	0.000435	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—TYK2—psoriasis	7.33e-06	0.000434	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—TYK2—psoriasis	7.26e-06	0.000429	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CXCL8—psoriasis	7.05e-06	0.000417	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—CXCL8—psoriasis	7.03e-06	0.000416	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CXCL8—psoriasis	6.96e-06	0.000412	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—APOE—psoriasis	6.79e-06	0.000401	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TYK2—psoriasis	6.44e-06	0.000381	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CXCL8—psoriasis	6.4e-06	0.000379	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CXCL8—psoriasis	6.38e-06	0.000378	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CXCL8—psoriasis	6.32e-06	0.000374	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TYK2—psoriasis	6.17e-06	0.000365	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PPARG—psoriasis	5.91e-06	0.00035	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—APOE—psoriasis	5.69e-06	0.000337	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—LEP—psoriasis	5.69e-06	0.000337	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CAT—psoriasis	5.68e-06	0.000336	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—APOE—psoriasis	5.67e-06	0.000336	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—LEP—psoriasis	5.67e-06	0.000336	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—LEP—psoriasis	5.62e-06	0.000332	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—APOE—psoriasis	5.62e-06	0.000332	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CXCL8—psoriasis	5.61e-06	0.000332	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CARM1—psoriasis	5.55e-06	0.000328	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CXCL8—psoriasis	5.37e-06	0.000318	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—IL6—psoriasis	5.33e-06	0.000316	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NFKBIA—psoriasis	5.3e-06	0.000314	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NFKBIA—psoriasis	5.29e-06	0.000313	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NFKBIA—psoriasis	5.24e-06	0.00031	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CAT—psoriasis	5.22e-06	0.000309	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—JUN—psoriasis	5.22e-06	0.000308	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CAT—psoriasis	5.18e-06	0.000306	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—IL6—psoriasis	5.11e-06	0.000302	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NFKB1—psoriasis	5.02e-06	0.000297	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—JUN—psoriasis	4.99e-06	0.000295	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NFKB1—psoriasis	4.81e-06	0.000284	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—VEGFA—psoriasis	4.56e-06	0.000269	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—STAT3—psoriasis	4.51e-06	0.000267	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—APOE—psoriasis	4.41e-06	0.000261	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—VEGFA—psoriasis	4.36e-06	0.000258	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TYK2—psoriasis	4.34e-06	0.000257	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TYK2—psoriasis	4.33e-06	0.000256	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—STAT3—psoriasis	4.32e-06	0.000256	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TYK2—psoriasis	4.29e-06	0.000254	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—APOE—psoriasis	4.06e-06	0.00024	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—APOE—psoriasis	4.02e-06	0.000238	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPARG—psoriasis	3.84e-06	0.000227	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCL8—psoriasis	3.78e-06	0.000224	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCL8—psoriasis	3.77e-06	0.000223	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCL8—psoriasis	3.73e-06	0.000221	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL6—psoriasis	3.6e-06	0.000213	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL6—psoriasis	3.59e-06	0.000212	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL6—psoriasis	3.55e-06	0.00021	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPARG—psoriasis	3.53e-06	0.000209	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—JUN—psoriasis	3.52e-06	0.000208	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—JUN—psoriasis	3.51e-06	0.000207	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPARG—psoriasis	3.5e-06	0.000207	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—JUN—psoriasis	3.47e-06	0.000205	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—psoriasis	3.44e-06	0.000204	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CAT—psoriasis	3.41e-06	0.000202	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NFKB1—psoriasis	3.38e-06	0.0002	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NFKB1—psoriasis	3.37e-06	0.0002	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NFKB1—psoriasis	3.34e-06	0.000198	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—psoriasis	3.3e-06	0.000195	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL6—psoriasis	3.15e-06	0.000186	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—VEGFA—psoriasis	3.07e-06	0.000182	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—VEGFA—psoriasis	3.06e-06	0.000181	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—STAT3—psoriasis	3.04e-06	0.00018	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—VEGFA—psoriasis	3.03e-06	0.000179	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—STAT3—psoriasis	3.03e-06	0.000179	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL6—psoriasis	3.02e-06	0.000178	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—STAT3—psoriasis	3e-06	0.000178	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOE—psoriasis	2.65e-06	0.000157	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—psoriasis	2.32e-06	0.000137	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—psoriasis	2.31e-06	0.000137	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPARG—psoriasis	2.31e-06	0.000137	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—psoriasis	2.29e-06	0.000136	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL6—psoriasis	2.12e-06	0.000126	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL6—psoriasis	2.12e-06	0.000125	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL6—psoriasis	2.1e-06	0.000124	CbGpPWpGaD
